Many Groups and Organizations respond to Policy Issues WASHINGTON, July 10, 2025 /PRNewswire/ -- The recent rapid approach to policy...
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements...
Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug...
Chicago, Illinois--(Newsfile Corp. - July 3, 2025) - Morgan AH Medical made headlines at this year's Abilities Expo Chicago (June...
GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative...
MISSION, Kan., June 30, 2025 /PRNewswire/ -- (Family Features) With school out for summer, children will be away from teachers...
Dearborn Group shifts focus to core health offerings as Symetra adds scale to growing Workforce Benefits business Symetra to become...
Guidance also outlines metabolic evaluation – like Baylor Genetics’ unique Global MAPS® untargeted metabolite screen – as second-tier testHOUSTON, June...
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...
New funding supports market launch of Empo's pioneering at-home monitoring system to help prevent diabetic amputations and reduce healthcare costs...
(CSE: PPB / FSE: 3QG / US: PPBGF)investor@p2p-group.com Highlights: Evaluation deployment originated by a major provider from inbound demand and...
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the opportunity to take advantage of...
Many Groups and Organizations respond on Policy Issues WASHINGTON, June 12, 2025 /PRNewswire/ -- The recent rapid approach to policy...
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral...
Dr. Jon Block to Lead Vivex’s Completion of its Ascend and Restore Randomized Clinical Trials for VIA Disc® NP, Vivex’s...
WELLESLEY, Mass. and NEW YORK, June 9, 2025 /PRNewswire/ -- Sun Life U.S., a top ten group benefits provider, and...
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...